Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Gan & Lee Pharmaceuticals. (603087.SS)
CNY69.69
-0.31 (-0.44%)
CN SHH Healthcare Medical - Instruments & Supplies
Address
No. 8, Nanfeng West 1st Street 101109
Beijing, CN
Beijing, CN
CEO
Zhongru Gan
Website
ganlee.com
IPO
2020-06-29
ISIN CNE100003ZH1
Description
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY69.69
-0.31 (-0.44%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
0.49
Float Shares
319.44M
Free Float %
53.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.45% | -3.36% | -11.16% | -20.75% | -17.89% | -23.20% | -4.07% | +35.30% | -59.78% | -19.73% | -19.73% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
69.69
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
23.90
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+33.1% ★ Q1'26: -10.8% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+85.6% ★ Q1'26: -37.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+8.2% ★ Q1'26: -12.1% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+18.8% ★ Q1'26: +21.2% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+8.9% ★ Q1'26: +8.0% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.3% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.11× ★ Q1'26: 0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.36B
est: 3.43B (-2.0%)
|
3.61B
est: 3.79B (-4.6%)
|
1.71B
est: 4.00B (-57.2%)
|
2.61B
est: 2.69B (-3.2%)
|
3.05B
est: 3.35B (-9.0%)
|
4.05B
est: 4.15B (-2.4%)
|
4.71B
4.71B – 4.72B
+13.6% YoY
|
5.51B
5.38B – 5.64B
+16.8% YoY
|
6.36B
6.34B – 6.38B
+15.5% YoY
|
| EBITDA |
1.57B
est: 655.86M (+140.1%)
|
1.57B
est: 723.72M (+117.1%)
|
-479.87M
est: 765.01M (-162.7%)
|
400.79M
est: 404.17M (-0.8%)
|
545.57M
est: 502.46M (+8.6%)
|
1.07B
est: 622.80M (+71.1%)
|
707.59M
706.10M – 709.08M
+13.6% YoY
|
826.45M
807.20M – 845.70M
+16.8% YoY
|
954.53M
950.88M – 958.18M
+15.5% YoY
|
| EBIT |
1.41B
est: 395.85M (+257.4%)
|
1.39B
est: 436.81M (+218.3%)
|
-675.68M
est: 461.73M (-246.3%)
|
180.03M
est: 185.09M (-2.7%)
|
294.58M
est: 230.10M (+28.0%)
|
760.13M
est: 285.21M (+166.5%)
|
324.03M
323.35M – 324.72M
+13.6% YoY
|
378.46M
369.65M – 387.28M
+16.8% YoY
|
437.12M
435.44M – 438.79M
+15.5% YoY
|
| Net Income |
1.23B
est: 1.38B (-10.6%)
|
1.45B
est: 1.51B (-4.0%)
|
-439.52M
est: 1.61B (-127.2%)
|
340.07M
est: 515.42M (-34.0%)
|
614.66M
est: 642.90M (-4.4%)
|
1.14B
est: 1.07B (+6.6%)
|
1.37B
1.32B – 1.45B
+27.8% YoY
|
1.60B
1.52B – 1.73B
+16.8% YoY
|
1.89B
1.76B – 2.09B
+18.0% YoY
|
| SGA |
1.20B
est: 1.12B (+6.6%)
|
848.05M
est: 1.24B (-31.5%)
|
875.66M
est: 1.31B (-33.1%)
|
668.23M
est: 813.05M (-17.8%)
|
842.18M
est: 1.01B (-16.7%)
|
934.08M
est: 1.25B (-25.4%)
|
1.42B
1.42B – 1.43B
+13.6% YoY
|
1.66B
1.62B – 1.70B
+16.8% YoY
|
1.92B
1.91B – 1.93B
+15.5% YoY
|
| EPS |
2.19
est: 2.33 (-6.0%)
|
2.59
est: 2.56 (+1.2%)
|
-0.78
est: 2.73 (-128.6%)
|
0.60
est: 0.87 (-31.0%)
|
1.04
est: 1.09 (-4.1%)
|
1.93
est: 1.81 (+6.6%)
|
2.34
2.23 – 2.45
+29.4% YoY
|
2.75
2.57 – 2.92
+17.2% YoY
|
3.25
2.97 – 3.53
+18.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 3/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
481.17M
OE per share TTM
0.82
Owner's Yield
1.57%
Maintenance CapEx ratio
217.16%
Maint CapEx / Avg PPE
102.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 37 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X China Biotech ETF (HKD) 2820.HK | 2.21% | 1.77M | 0.68% |
| 2 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.23% | 85.2K | 0.65% |
| 3 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.07% | 11.4K | 0.65% |
| 4 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.06% | 43.1K | 0.55% |
| 5 | Franklin Emerging Market Core Dividend Tilt Index ETF DIEM | 0.02% | 16.7K | 0.19% |
| 6 | Franklin FTSE China ETF FLCH | 0.02% | 64.7K | 0.19% |
| 7 | Franklin FTSE China UCITS ETF FLXC.L | 0.02% | 273.4K | 0.19% |
| 8 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 8.3K | 0.15% |
| 9 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 473.3K | 0.06% |
| 10 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 203.0K | 0.17% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
169.6K
Shares Outstanding
597.30M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cheng Sun | Chief Financial Officer & Deputy GM | — | male |
| Cheng Xing | Deputy General Manager | — | female |
| Jiaxin Wang | Supervisor & Archives Manager | — | female |
| John Wang | Senior VP & Chief Strategy Officer | — | — |
| Kai Du | GM & Director | — | male |
| Li Zhou | Head of Accounting | — | — |
| Qianming Wang | Chief Financial Officer | — | male |
| Rong Zou | Secretary | — | female |
| Ting Jia | Chief Medical Officer | — | — |
| Wei Chen | Deputy GM & Director | — | male |
| Weiqiang Song | Deputy GM & Director | — | male |
| Yajuan Feng | Head of Administrative Department & Supervisor | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603087.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
